Oxford Nanopore Demonstrates Label-Free Method for DNA Sequencing



By Kevin Davies

February 22, 2009 | In an important paper published online this week in the journal Nature Nanotechnology, scientists at Oxford Nanopore Technologies present the first proof-of-principle of their label-free next-generation sequencing system.

The paper*, by James Clarke and colleagues, shows that an engineered nanopore complex can discriminate between the four bases of DNA (A, C, T and G) with remarkable specificity, and can even identify methylated C residues (“the fifth base”) for good measure. The senior author of the report is Hagan Bayley, Oxford University chemistry professor and co-founder of Oxford Nanopore, who has been leading research into nanopores as detectors for sequencing and other applications for over a decade.

There is immense appeal in a DNA sequencing technology that dispenses with fluorescently tagged molecules, CCD cameras, and expensive microscopes, and thus has the makings of an affordable, real-time, label-free sequencing system. The Oxford Nanopore Nature Nanotechnology paper does not go so far as describing a prototype device or even reading the sequence of a DNA molecule. But it does is show that Oxford scientists have engineered the alpha-hemolysin nanopore to the point that it can efficiently discriminate between the four natural bases of DNA at speeds suitable for high-throughput applications.

Oxford Figure
Nanopores have shown considerable potential for DNA sequencing for more than a decade, but single-stranded DNA molecules slide through the nanopore much too quickly to recognize individual bases. Taking a different tack, Bayley’s group showed a few years ago that it could partially identify individual bases as they dropped through a nanopore by the degree to which they impeded the current flowing across the membrane housing the nanopore.

Building upon that work, Clarke and coworkers genetically engineered the alpha-hemolysin to find the best location to covalently attach a molecule of cyclodextrin -- a kind of washer that sits in the middle of the pore. The result is a molecular machine – a ring-like assembly of seven subunits, one of which has been modified to clamp the cyclodextrin -- that recognizes virtually every base passing through the pore.

By altering variables such as salt concentration, pH and temperature, Clarke and colleagues found conditions that allowed them to resolve the four bases to an accuracy of about 99.8%. The slight difference in size of the four bases results in a discrete blockage of the pore, which is read as a reproducible dip in the applied current from a baseline of around 60 picoamps to anywhere from 20-40 picoamps. In the current system, bases can be identified as they flow through the nanopore at a rate of about 25 per second.

Next Steps

Clarke and colleagues conclude that they have “solve[d] the key technical problems required for real-time, high-resolution nucleoside monophosphate detection.” They go on to state: “These advances represent the realization of a complete nanopore base detector, which, when combined with a compatible exonuclease DNA processing system, will provide the basis of a complete nanopore sequencer.”

That indeed is the next crucial step for Oxford Nanopore – to couple an exonuclease enzyme to the nanopore so that single bases are cleaved off a template DNA strand and their identity read off instantaneously as they funnel through the nanopore. Clark and colleagues conclude the Nature Nanotechnology paper by showing that the nanopore does indeed work in salt conditions favoring exonuclease activity and can detect bases cleaved off DNA strands in solution by the enzyme.

Oxford Nanopore was founded in 2005 and is located on the outskirts of Oxford, UK. Last month, the company announced an $18-million sales and distribution deal with Illumina for its exonuclease-based sequencing technology.

Editor’s note: Oxford Nanopore’s James Clarke will be presenting a poster on this work at CHI’s Next-Generation Sequencing conference, March 17-19, in San Diego.

*FURTHER READING: Clarke, J. et al. “Continuous base identification for single-molecule nanopore DNA sequencing.” Nature Nanotech. 2009.

Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1



White Papers & Special Reports

sgi - whp 1
Turning Genomics Data into Practical Insight
Sponsored by SGI

With worldwide sequencing capacity approaching 13 quadrillion DNA bases annually turning genomics data into knowledge is a true computational challenge. Read this paper and learn how the SGI UV coherent shared memory platform can:  

  • Speed results time while cost competitively tackling the most difficult computational problems across all omics disciplines. 
  • Push performance by scaling to extraordinary levels, up to 256 sockets (2,560 cores, 4,096 threads) per single system (one OS image). 

Provide support for up to 16TB of coherent shared memory in a single system image enabling extreme efficiency across a wide range of compute demands. 



accerlys-logo_2012_wh
New Complimentary Market Survey…
Collaborations and Communications Within Drug Discovery Research
Sponsored by Accelrys
This survey was conducted by the Cambridge Healthtech Media Group in January, 2012. It was sponsored by Accelrys related to their HEOS initiative to gather valid information around externalizing collaborative research while improving communications in the cloud. With 310 qualified industry respondents the survey findings reveal useful usage and trends patterns.  An insightful follow-on discussion and webinar related to this survey, and the HEOS by Scynexis SaaS portal is also available on the Bio-IT World website for complementary viewing.
 


Job Openings

tessella logo 
Scientific Software Engineer
Boston MA
$70,000 to $95,000
 

Tessella delivers software engineering and consulting services to leading pharmaceutical and biotech companies. We are recruiting Software Engineersto work with skilled bioinformaticians and scientists to identify business needs and recommend and develop technical solutions. Applicants require BS, MS or PhD in bioinformatics, biology or chemistry and 2+ years of software development in either: Java, C#, C++, C or VB.NET. 

Apply at http://jobs.tessella.com   

 

oxford nanopore logo 


 Early Access Collaborations Managers
Oxford Nanopore Technologies is developing a novel technology, GridIONTM for the direct, electronic analysis of DNA/RNA and other analytes.  As the system approaches the market, we are building a team of technically knowledgeable, highly motivated candidates with excellent customer service and facilitation skills to join our company as Collaboration Managers.  This is a unique opportunity to work with world-leading genomics customers throughout the early adoption phase of a new generation of DNA sequencing technology.. This is a facilitative, enabling role with responsibility for managing technology development collaborations with key customers at leading genomics institutions.  It will include long term management of the collaboration plan and milestones and associated meetings and documentation. Click here to find out more and apply   

Oxford Nanopore's GridION technology, VP, Sales and Marketing Oxford Nanopore Technologies is a fast-moving technology company that is developing a novel electronic molecular analysis technology. The technology is adaptable for the analysis of DNA/RNA, proteins, chemicals and other molecules.  It is therefore suitable for use in a variety of markets including scientific research and clinical applications.  As the technology approaches the market, Oxford Nanopore is seeking a visionary VP of sales and marketing to join the senior team.  The candidate will embrace the opportunities afforded by entering the market with a truly disruptive technology that has the potential to expand the number of users and the variety of applications in each target market.  This is a rare opportunity to influence the commercial strategy at an early phase of its commercial lifetime, in a well funded company.  Oxford Nanopore welcomes applications from candidates with a track record of high-level strategic commercial  leadership, who wish to apply a fresh approach to existing markets.  Experience in Life Sciences/DNA sequencing is central to this role, however we will consider your application if you have experience of disruptive technologies in other related industries.  We are particularly interested in candidates with strong expertise in the use of digital technologies for sales and marketing of scientific/technical products.  Click to  Apply  


 

For reprints and/or copyright permission, please contact  Tim McLucas, (781) 972-1342, tmclucas@healthtech.com .